Prospective observational study of imatinib therapy in japanese patients with advanced gastrointestinal stromal tumors: Long-term follow-up and second malignancy

Japanese Journal of Clinical Oncology

Volumn 42, Issue 7, 2012, Pages 578-585

  Kanda, Tatsuo ^a   Ishikawa, Takashi ^a   Hirota, Seiichi ^b   Yajima, Kazuhito ^a   Kosugi, Shin ichi ^a   Ohashi, Manabu ^c   Suzuki, Satoshi ^d   Mashima, Yasuoki ^e   Ajioka, Yoichi ^a   Hatakeyama, Katsuyoshi ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d Tsuruoka Municipal Shonai Hospital   (Japan)

^e Tachikawa PET Center   (Japan)

Author keywords

Gastrointestinal stromal tumor; Imatinib mesylate; Long term outcomes; Molecularly targeting therapy; Second malignancies

Indexed keywords

CALCIUM; IMATINIB; PHOSPHATE; POTASSIUM; SODIUM;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; EDEMA; EOSINOPHIL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INOPERABLE CANCER; JAPANESE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; NAUSEA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; SECOND CANCER; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL TRACT CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PIPERAZINES; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864344190     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys056     Document Type: Article

References (24)

1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human. Science 1998;279:577-80.
2. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
3. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010;8(Suppl 2):S1-41.
4. Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 2):v98-102.
5. Kubota T. Gastrointestinal stromal tumor (GIST) and imatinib. Int J Clin Oncol 2006;11:184-9.
6. Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006;93:304-11.
7. Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007;245:341-6.
8. Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomized phase 3 trial. Lancet Oncol 2010;11:942-9.
9. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
10. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-5.
11. Brass EP. The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther 2010;87:351-5.
12. Nishida T, Shirao K, Sawaki A, et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 2008;13:244-51.
13. van Oosteron AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001;358:1421-3.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
15. Ray-Coquard IL, Bui BN, Adenis A, et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: a French Sarcoma Group Study. J Clin Oncol 2010;28(Suppl):abstr10032.
16. Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009;27:3141-7.
17. Ryu MH, Kang WK, Bang YJ, et al. A prospective, multicenter, phase 2 study of imatinib mesylate in Korean patients with metastatic or unresectable gastrointestinal stromal tumor. Oncology 2009;76:326-32.
18. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-31.
19. DeMatteo RP, Maki RG, Singer S. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007;245:347-52.
20. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Japan Cancer Surveillance Research. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2012;41:139-47.
21. Novartis. Glivec (imatinib mesylate tablets): JPN prescribing information [online]. http://product.novartis.co.jp/gli/pi/pi_glitab.pdf.
22. Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol 2006;23:120-9.
23. Pandurengan RK, Dumont AG, Araujo DM, et al. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol 2010;21:2107-11.
24. Sevinc A, Seker M, Bilici A, et al. Co-existence of gastrointestinal stromal tumors with other primary neoplasms. Hepatogastroenterology 2011;58:824-30.